Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. - Wikidata - awgldk - TriplyDB

Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.

Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.

http://www.wikidata.org/entity/Q45256460

about

Non-dietary forms of treatment for adult celiac disease Therapeutic approaches for celiac disease Non-dietary methods in the treatment of celiac disease Non-systemic drugs: a critical review Novel therapeutic/integrative approaches for celiac disease and dermatitis herpetiformis Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions.Coeliac disease and gluten-related disorders in childhood Celiac disease: From pathophysiology to treatment.The present and the future in the diagnosis and management of celiac disease.Celiac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms.Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease Celiac disease: advances in treatment via gluten modification Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers.Future treatment strategies for celiac disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Recent advances in the development of new treatments for celiac disease.Latest in vitro and in vivo models of celiac disease.Current trends and investigative developments in celiac disease.Advances in the treatment of coeliac disease: an immunopathogenic perspective.Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.Current status of drugs in development for celiac disease.Emerging drugs for coeliac disease.Emerging drugs for celiac disease.Celiac disease 2015 update: new therapies.Immunopathogenesis and therapeutic approaches in pediatric celiac disease.Current Status of Celiac Disease Drug Development.Current and novel therapeutic strategies in celiac disease.Gluten-related disorders: certainties, questions and doubts.Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge.Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease.New Insights into the Pathogenesis of Celiac Disease.Effect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease.The burden of celiac disease in Canada: more work needed to lighten the load.Celiac disease: a challenging disease for pharmaceutical scientists.Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten.Editorial: enhancing gluten digestion in the stomach - a further help to minimise unintentional ingestion?Autoimmune phenotypes in schizophrenia reveal novel treatment targets.Celiac disease A Grounded Guide to Gluten: How Modern Genotypes and Processing Impact Wheat Sensitivity

P2860

Q24602271-E71AE407-524A-4B39-8D80-664C41A9AEFE Q26825413-AA4C2480-0039-47DF-AF09-D069B67231BC Q26863359-32874B69-E38B-4995-9217-52804DADC986 Q26863371-293C6506-F9B2-4C8D-BAFE-D88628EC35CF Q27010008-F8C01A60-9257-45B4-8929-B45563D15174 Q27336477-559D0B89-E5B2-4930-A402-CFD7A287DB02 Q28263872-45105E56-6139-42D3-BC02-EBAEA1E636BF Q30234291-387F3B84-4D79-4AE3-AA16-74CA9E105512 Q34444067-A9E435F5-8325-4748-8AC5-872134B9A4C8 Q34809320-D81ADE05-F5F9-4987-B95F-A16595E4E729 Q35647827-56481FA4-C8D7-48BF-8621-8CF5E5522B3D Q37144602-CEBA6720-FAB8-4DE4-BCC5-07E9CDC40B1F Q37210843-2D2B759D-F143-4DC3-BDDF-7DF45C3BD97A Q37275552-6FECAE63-65A6-41F7-B284-899335CB35B2 Q38012460-CA662A31-3D8F-47DD-AC71-C124833C5078 Q38016781-16EB8C50-50F2-4E03-8965-3E268D1D37A7 Q38038684-C8C982B7-011D-4A78-8770-341851B86D03 Q38072065-E2D17FC0-0341-498C-9964-9EE6505DAB6D Q38123864-F3B13020-731E-4182-BC3E-30CEE9ECEBDC Q38126789-2BEB9436-D843-4A4F-AE98-8E24B2E271F5 Q38159436-816F2A5A-3D6A-4CFF-944F-288B2E39A135 Q38210088-0C489DA2-91E0-4056-971B-4DF7F4D84B0E Q38248960-19E5043B-B645-4FBC-8268-E1C72AFDAD32 Q38286185-A55C1AED-68CC-4CDC-8794-B3D0727F7E63 Q38416745-A06B7D1F-6BB0-4118-9950-D8DD350F385E Q38783192-4E9EB248-A7D0-4801-AA4A-37632AC622CB Q38791641-F11DAF72-5A1C-4A05-837C-A2C3EDF8EB02 Q38870456-80C3DBA8-740F-4911-A6EB-7CA748A8CF21 Q39277546-7143868D-BD29-4DB3-87F5-6A56E9106386 Q39762024-E5B0ED54-3869-48DA-9508-4F19226453CE Q41546021-D8F5EBA3-AA3E-4675-9B60-BE251AD6B3DB Q41605556-075ED9A4-9612-4F65-A3B5-E8210D2909D4 Q41840254-AD9E1432-A2B3-435E-8B42-21BE08F3350F Q42409212-EF28A274-862B-4D58-954D-23E12699E64E Q45254873-B10E3977-7D71-4AE5-80E1-98097C0739EA Q46817256-F76D39F6-0C29-4D18-9084-DB263C312BBE Q53794329-F007E55B-7551-45E1-A3DE-70A544298988 Q54217096-50C533CD-1247-485B-B617-AB92ED5687DF Q56853178-FF538F38-24A6-4B27-9549-778F41971AE4 Q57534899-5651303F-17FB-4660-8BA4-DF5D69B0391D

P2860

Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.

http://www.wikidata.org/entity/Q45256460

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Safety, tolerability, and acti ...... calating-dose clinical trials.

@en

Safety, tolerability, and acti ...... calating-dose clinical trials.

@nl

type

label

Safety, tolerability, and acti ...... calating-dose clinical trials.

@en

Safety, tolerability, and acti ...... calating-dose clinical trials.

@nl

prefLabel

Safety, tolerability, and acti ...... calating-dose clinical trials.

@en

Safety, tolerability, and acti ...... calating-dose clinical trials.

@nl

P1433

Q45256460-1236138A-2464-4289-A28D-6EC02B13B18E

P1476

Q45256460-DEAA93DD-DB83-480A-9051-C9B213E5BBA5

P2093

Q45256460-0DD5332E-A92B-4CDF-A0E6-383AAACF865C

Q45256460-18B07F20-7067-4CF1-B463-1DCD3DD58428

Q45256460-335AF0DB-CBC9-4812-8567-E5FEFFB0BE93

Q45256460-719A4D62-5ED6-4951-92B2-80FFFD43CD9D

Q45256460-881B7F81-2018-46EB-A474-4D851791EBE2

Q45256460-962DE772-DC81-4CB2-85B2-EEAA5595F3F3

Q45256460-AFACF2D6-FA5F-44D3-B12F-88738012EB5D

Q45256460-BEE0285F-A307-49E2-B335-048D3D72D04B

Q45256460-E3557312-B5A1-4DEA-88FD-0AEE324B6FAD

Q45256460-FC65E466-33D8-4298-B4AC-D8CA1DF9690B

P2860

Q45256460-014C543F-C847-4F66-ADDA-CBC120E2468A

Q45256460-06DFA4AC-9CBD-4A49-8BC7-9BA73F277946

Q45256460-08368AA1-7828-4307-829E-5ACDBB3E8CB7

Q45256460-24C09C3B-1CAB-4D08-A0BC-EDFF0062A51C

Q45256460-2738212B-1D31-40E3-B53F-D3A3A6938668

Q45256460-3C35E79D-F5CA-43D2-BFF0-F09F8B29FE80

Q45256460-3CFD75A7-0FA9-4D0C-99BA-6C853AC4B5E1

Q45256460-516D9CAF-9A34-42D0-B921-62417DAF6B61

Q45256460-52209A3B-8CF9-43CC-8650-6D485A514AEA

Q45256460-65EE491B-23D0-4EE2-8358-52FDB4E699A0

P2888

Q45256460-48ECE526-3E82-41A3-9B55-EEFA68AF6FE5

P304

Q45256460-948C8586-3DCC-4630-919E-DD99B53C0D65

P31

Q45256460-3D4FE6C5-64DA-49B0-8A58-BBEC7F7EE22A

P356

Q45256460-D64951E3-B0E1-4C88-B9F8-C3CC7E883B4C

P433

Q45256460-5AEAF45C-E27F-45C8-9787-6A8F2CC367BA

P478

Q45256460-EE2123B3-E6F7-4638-9180-38A3A9C193CB

P577

Q45256460-A0BC12E0-3369-48E9-91B6-EF01355CA42E

P6179

Q45256460-AF182C41-F3D0-4111-A822-3FEB8C75905B

P698

Q45256460-4D0ECF47-6E9D-4B7C-ABB3-C41FDF07B74C

P921

Q45256460-936ED13F-F1EF-4D8E-A21A-6084598D0484

P356

S10620-011-1906-5

P1433

Digestive Diseases and Sciences

P1476

Safety, tolerability, and acti ...... calating-dose clinical trials.

@en

P2093

Andrew G Spencer

http://www.w3.org/2001/XMLSchema#string

Daniel C Adelman

http://www.w3.org/2001/XMLSchema#string

Kenji Kozuka

http://www.w3.org/2001/XMLSchema#string

Matthew Siegel

http://www.w3.org/2001/XMLSchema#string

Mitchell E Garber

http://www.w3.org/2001/XMLSchema#string

Pawan Kumar

http://www.w3.org/2001/XMLSchema#string

Revati Shreeniwas

http://www.w3.org/2001/XMLSchema#string

Robert N Williams

http://www.w3.org/2001/XMLSchema#string

Vijaya Pratha

http://www.w3.org/2001/XMLSchema#string

Wendy Botwick

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue

Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease

Structural basis for gluten intolerance in celiac sprue

Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide.

Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet

Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues.

Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study.

Prevalence of Celiac disease among children in Finland.

Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease.

Rational design of combination enzyme therapy for celiac sprue.

P2888

s10620-011-1906-5

P304

440-450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-011-1906-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050798381

http://www.w3.org/2001/XMLSchema#string

P698

21948339

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial